MIR378C: A Potential Drug Target and Biomarker (G100422867)
MIR378C: A Potential Drug Target and Biomarker
MIR378C is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of cytoplasmic user parameters (SUPPORT), which includes proteins that play important roles in various cellular processes, including cell signaling, DNA replication, and stress response. One of the unique features of MIR378C is its ability to interact with multiple signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway. This suggests that MIR378C may be a drug target that can be modulated by small molecules to treat a variety of diseases.
MIR378C is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is a member of the superfamily of cytoplasmic user parameters (SUPPORT), which includes proteins that play important roles in various cellular processes, including cell signaling, DNA replication, and stress response. One of the unique features of MIR378C is its ability to interact with multiple signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway.
The TGF-β pathway is a well-established signaling pathway that plays a role in various cellular processes, including cell growth, differentiation, and inflammation. The TGF-β pathway is activated by the cytoplasmic protein SMAD, which can bind to the TGF-β receptor. MIR378C has been shown to interact with SMAD, which suggests that it may be a regulatory protein that plays a role in the TGF-β pathway.
The PI3K/Akt pathway is a signaling pathway that is involved in various cellular processes, including cell survival, angiogenesis, and inflammation. The PI3K/Akt pathway is activated by the cytoplasmic protein PDGF-B, which can bind to the PI3K receptor. MIR378C has been shown to interact with PDGF-B, which suggests that it may be a regulatory protein that plays a role in the PI3K/Akt pathway.
MIR378C is also involved in the regulation of cellular processes that are important for the development and maintenance of tissues. For example, MIR378C has been shown to be involved in the regulation of cell proliferation, differentiation, and survival. It has been shown to interact with various cytoplasmic proteins, including the transcription factor p21, which is involved in the regulation of cell growth and apoptosis.
In addition to its involvement in cellular signaling pathways, MIR378C is also thought to be involved in the regulation of various biological processes that are important for overall health. For example, MIR378C has been shown to be involved in the regulation of inflammation, pain perception, and sleep. It has been shown to interact with various cytoplasmic proteins, including the chemokine IL-1尾, which is involved in the regulation of inflammation and pain perception.
Given the unique combination of features that MIR378C has, it is possible that it may be a drug target that can be modulated by small molecules. This could have the potential to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.
MIR378C is currently being investigated as a potential drug target by researchers, who are working to identify small molecules that can modulate its activity. This research has the potential to lead to the development of new treatments for a variety of diseases.
Protein Name: MicroRNA 378c
The "MIR378C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR378C comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR378D1 | MIR378D2 | MIR378E | MIR378F | MIR378G | MIR378H | MIR378I | MIR379 | MIR380 | MIR381 | MIR382 | MIR383 | MIR384 | MIR3907 | MIR3908 | MIR3909 | MIR3910-1 | MIR3910-2 | MIR3911 | MIR3912 | MIR3913-1 | MIR3913-2 | MIR3914-1 | MIR3914-2 | MIR3915 | MIR3916 | MIR3917 | MIR3918 | MIR3919 | MIR3920 | MIR3921 | MIR3922 | MIR3923 | MIR3924 | MIR3925 | MIR3926-1 | MIR3926-2 | MIR3927 | MIR3928 | MIR3929 | MIR3934 | MIR3935 | MIR3936 | MIR3936HG | MIR3937 | MIR3938 | MIR3939 | MIR3940 | MIR3941 | MIR3942 | MIR3943 | MIR3944 | MIR3945 | MIR3945HG | MIR3960 | MIR3972 | MIR3973 | MIR3974 | MIR3976 | MIR3976HG | MIR3977 | MIR3978 | MIR409 | MIR410 | MIR411 | MIR412 | MIR421 | MIR422A | MIR423 | MIR424 | MIR425 | MIR4251 | MIR4252 | MIR4253 | MIR4254 | MIR4255 | MIR4256 | MIR4257 | MIR4258 | MIR4259 | MIR4260 | MIR4261 | MIR4262 | MIR4263 | MIR4264 | MIR4265 | MIR4266 | MIR4267 | MIR4268 | MIR4269 | MIR4270 | MIR4271 | MIR4272 | MIR4273 | MIR4274 | MIR4275 | MIR4276 | MIR4277 | MIR4278 | MIR4279
